Shenzhen Kangtai Biological Products Co.,Ltd.

It is a modern science and technology enterprise oriented by health, and an international vaccine enterprise striving to build the great wall of national health protection. It has the domestic first quadruple vaccine with independent intellectual property rights, and grasps the commanding height of world vaccine science and technology frontier technology. The company has more than 30 research projects, of which 3 have applied for drug registration approval, and the development of oral five valent reconstituted live attenuated rotavirus vaccine, four valent hand foot mouth disease vaccine, mumps Feng Shui pox vaccine and other multi valent vaccines has been arranged. The company is located at No.6 Kefa Road, Science Park, Nanshan District, Shenzhen, with a registered capital of 634 million yuan.

The company's main business is R & D, production and sales of vaccines for human use. Its products cover immunization planning and non immunization planning vaccines. At present, its main products include recombinant hepatitis B vaccine (Saccharomyces cerevisiae), Haemophilus influenzae type b conjugate vaccine, live attenuated measles and rubella vaccine, acellular pertussis type B Haemophilus influenzae vaccine 23 valent pneumococcal polysaccharide vaccine and other products.

Since its establishment in 1992, Kangtai biology has undertaken a number of national, provincial and municipal key scientific research projects and technology development tasks, and has possessed the core competitiveness of research and development and industrialization of new technologies such as multi valent vaccine and genetic engineering vaccine. The company has 8 R & D carriers including academician and expert workstation, and its products cover more than 30 provinces and autonomous regions. Among them, the independent development of acellular DPT vaccine combined with Haemophilus influenzae type B is the exclusive innovative quadruple vaccine in China. It is specially targeted at the 60 microgram hepatitis B vaccine for non responders, and it has the title of "national key new product".

After more than 20 years of unremitting efforts, Kangtai biology has developed into a high-tech enterprise with complete R & D varieties, rich product lines and obvious technical advantages, and plays an important role in the national immunization front. Only hepatitis B vaccine, Kangtai biological production and sales of more than 1 billion 200 million doses, to help more than 400 million people to avoid hepatitis B virus damage, for the state to reduce public health spending more than 160 billion yuan, has extremely important economic and social value.